Knight Therapeutics Launches Canadian Sales Of ADHD Medication JORNAY PM For Children

Knight Therapeutics Inc., (Knight), a pan-American (ex-USA) specialty pharmaceutical company, announced the launch of JORNAY PM (methylphenidate HCI extended-release capsules) in Canada. JORNAY PM is a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children 6-12 years of age. In May 2024, Knight entered into an agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (now part of Collegium Pharmaceutical, Inc.), for the exclusive rights to distribute JORNAY PM in Canada and Latin America. Knight received the approval of JORNAY PM by Health Canada in November . . .